Dec 21 (Reuters) - Jazz Pharmaceuticals Plc:
* JAZZ PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION FOR SOLRIAMFETOL (JZP-110) FOR EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY AND OBSTRUCTIVE SLEEP APNEA
* JAZZ PHARMACEUTICALS PLC - SUBMISSION OF NDA TO U.S. FDA SEEKING MARKETING APPROVAL FOR SOLRIAMFETOL Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.